Courage Against Cancer
At Courage Against Cancer (CAC), we believe every patient deserves evidence-based answers to the most pressing questions surrounding emerging therapies — including the question driving significant research interest today: What does preclinical research show about fenbendazole and colorectal cance…
At Courage Against Cancer (CAC), we believe cancer patients deserve evidence-based answers to the pillar article’s primary question — not just viral anecdotes. Fenbendazole, a veterinary antiparasitic drug, has generated significant online attention regarding colorectal cancer.
At Courage Against Cancer (CAC), our mission is to provide evidence-based answers to the pressing question: Could fenbendazole play a role in colorectal cancer care? Laboratory research has proposed several biological mechanisms.
The National Cancer Institute (NCI) is investigating ivermectin’s potential anticancer properties through preclinical research, which is distinct from commercial claims and the controversial Hulscher et al. 2026 study. NCI’s findings are not clinical endorsements, highlighting the need for caution regarding off-label uses and overlapping commercial interests in cancer treatment discussions.